Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Oct 2014

Rudaitis Vilius, Zvirblis Tadas, Kanopiene Daiva, Janulynaite Dovile, Griskevicius Laimonas, Janavicius Ramunas

Abstract excerpt

OBJECTIVE: The aim of this study was to explore BRCA mutation frequency and to evaluate its impact on prognosis of advanced-stage ovarian cancer patients treated with debulking surgery and platinum-based chemotherapy. METHODS: Patients with advanced-stage epithelial ovarian cancer were enrolled in a prospective, single-center study from September 2008 to December 2011. All cases were screened for BRCA1 and BRCA2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Disease-Free Survival

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Neoplasms, Glandular and Epithelial

Share to Ovariectomy

Source

Identifiers

PMID: 25248112
DOI: 10.1097/IGC.0000000000000247

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer.PMID 25248112Read ↗

Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis.Semantic proximity Read ↗

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancerSemantic proximity Read ↗

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.Semantic proximity Read ↗

Prognostic Significance of Clinical Factors Including BRCA Mutation in Epithelial Ovarian, Peritoneal, Fallopian Tube Cancer.Semantic proximity Read ↗

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.Semantic proximity Read ↗

The Impact of BRCA Mutation on the Efficacy of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.Semantic proximity Read ↗

Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.Semantic proximity Read ↗

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcomeSemantic proximity Read ↗

Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role.Semantic proximity Read ↗

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.Semantic proximity Read ↗

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.